Fig. 6.
![Fig. 6. The effect of delaying anti-Id MoAb-treatment in BCL1 lymphoma. Groups of 10 mice were given 106BCL1 on day 0 and then treated with MoAb (1 mg/mouse) 4 or 14 days later as shown. For comparison, an additional group of mice was treated with 131I–anti-Id MoAb (750 μg/animal [approximately 7.5 MBq]) on day 14. Treatment groups include: Control IgG (⋆); anti-Id on day 4 and 14 (□); 131I–anti-Id (▪); and anti-MHCII (○) on day 14.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/94/1/10.1182_blood.v94.1.233.413a25_233_243/6/blod41325006x.jpeg?Expires=1735839521&Signature=LZ~GGtVqeWSgseErsMFHa0tYONbQzDyp7UUku20qSQGB15MzUws9siah5tntUbmlnBd7LCcp~Wt0zD4iXrbA3QMkRlf5x0iG2WjWtwOvdwcR4aFmFn4RGLWXVvA6whMhyanYxST-gRtDDIXYMKVvy-KKAZ4h-yEuXzy84eQh3epUiCHXwPA4eo8rRJbBIdShQIdfqNSDOdmgQb2Q2tfdcq0bMvFAsj8QJkMAxATtr2CuuqEqDYSZ4xpNcXq7IBSncXwVI5OaqPWqxeHL4PqjeUfXhAH2es9df2YeiwX4sEfP8Q1~0bYu1iL8IM696qFGA-MozkyXoLXWFm~21YMjBA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
The effect of delaying anti-Id MoAb-treatment in BCL1 lymphoma. Groups of 10 mice were given 106BCL1 on day 0 and then treated with MoAb (1 mg/mouse) 4 or 14 days later as shown. For comparison, an additional group of mice was treated with 131I–anti-Id MoAb (750 μg/animal [approximately 7.5 MBq]) on day 14. Treatment groups include: Control IgG (⋆); anti-Id on day 4 and 14 (□); 131I–anti-Id (▪); and anti-MHCII (○) on day 14.
